Treatment of Dermatitis Herpetiformis When Dapsone Has Not Achieved Remission

This protocol covers the management of dermatitis herpetiformis in patients who have not achieved adequate clinical response or skin remission on the standard first-line regimen.

Prior treatment & failure condition

The first-line regimen — dapsone added to a lifelong gluten-free diet — did not produce the required clinical response or remission of skin manifestations.

The criterion for escalation is the failure to achieve clinical response within one week at an adequate daily dose of dapsone, without clinical remission of the skin manifestation.

Next-step approach

For patients who do not respond sufficiently to dapsone, the protocol identifies alternative therapeutic agents drawn from several different drug classes. The complete set of options, their clinical context, and supporting evidence are available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.17183

Less effective than dapsone, variable dosage (1-4 g/day sulfasalazine or 0.25-1.5 g/day sulfamethoxypyridazine). In Europe, sulfapyridine and sulfamethoxypyridazine are only approved for veterinary use.
Tetracycline 500 mg q.i.d. and nicotinamide 500 mg t.i.d.
Its usefulness cannot be judged currently
Published dosage in dangerous range (5-7 mg/kg body weight)
Partially effective, potentially severe side effects upon long-term use

View source ↗